At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time !
COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor agonists potentially offer new therapeutic options for the treatment of heart failure.
Menu